RARE | Page 3 | RegMed Investors

utility

header_second

RegMed Investors (RMi) went exclusive on July 27th!

Your complimentary subscription to RegMed Investors’ (RMi) reporting on the stem, cell and gene therapy and RegMed sector has expired.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

It’s up to you to choose the level of content access to provide a premium experience and value - don’t wait to exhale!

I also bring fresh perspectives that yield a whole that is greater than the sum of the parts as I convey a spectrum of factors that explain outcomes, analytical principles and analysis without the encumbrance of trading, investment or I-Banking.

So, after these years of following our facts … first and fast; be part of our “inner circle” as a subscriber!

Stay with me and join our coalition and have a seat at the appreciation table!

Login Sign up now Not now

content_top

34 companies, 1 interpreter! Insight, foresight
and recommendation

35.98

2.56

(256.00%)

content_middle

Previous Close:

33.42

52wk Range:

29.59 - 60.37

Market Capitalization:

0.00M

Shares Outstanding:

0.00M

content_right

February 22, 2016 - 8:03am | Henry'omics, Out and About
Bellicum’s (BLCM) BPX-501 granted Orphan Drug Designation
January 12, 2016 - 1:59pm | Research Notes, Henry'omics
Cytori (CYTX) inks pact with Clinigen Group’s Idis to launch...
December 30, 2015 - 10:56am | Regulatory
Regenxbio (RGNX) FDA has granted Rare Pediatric Disease designation
December 2, 2015 - 9:00am | Research Notes, Out and About
Cytori (CYTX) Clinical data demonstrates sustained two-year benefit in Scleroderma treatment - BUY
November 23, 2015 - 8:49am | Research Notes
Aduro Biotech (ADRO) Receives Orphan Drug Designation from EMA for CRS-207 for the Treatment of Mesothelioma. UP $1.17 or +4.06% to $30.00 in the pre-market
November 18, 2015 - 9:41am | Research Notes, Regulatory
Applied Genetic Technologies (AGTC) gets Orphan Status for its treatment of achromatopsia caused by mutations in the CNGA3 gene - BUY
October 2, 2015 - 7:00am | Research Notes, Regulatory
Regenxbio (RGNX) FDA grants Orphan Drug Designation for gene therapy treatment
September 22, 2015 - 7:03am | Research Notes, BOD & C-Suite Updates
ImmunoCellular Therapeutics (NYSEMKT: IMUC) Adds two new BOD members
July 16, 2015 - 10:28am | BOD & C-Suite Updates
uniQure (QURE) new SVP of R&D
June 8, 2015 - 10:30am | Out and About, Research Notes
Fibrocell (FCSC) and Intrexon (XON) positive in vitro pre-clinical data for FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) a rare, congenital, devastating skin disease
May 13, 2015 - 8:22am | Regulatory
Fibrocell (FCSC) receives Rare Pediatric Disease Designation from FDA for FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) and is UP +$0.69 or +16.38% in pre-market
March 30, 2015 - 10:08am | Out and About
After an ugly selloff last week, two (2) biotech, one (1) pharmacy benefit unit and one (1) cell based Monday mergers
February 27, 2015 - 9:31am | BOD & C-Suite Updates
Capricor Therapeutics (CAPR) New VP of Regulatory Affairs and Drug Development
January 30, 2015 - 7:09pm | Financings
Spark Therapeutics (ONCE) Gene-therapy company shares double in debut
January 20, 2015 - 10:06am | Research Notes
Verastem (VSTM) Orphan Medicinal Product Designation from EMA for VS-5584 in Mesothelioma
December 29, 2014 - 9:51am | BOD & C-Suite Updates
BioTime (NYSEMKT: BTX) appoints Mohanty COO
December 16, 2014 - 12:15pm | Research Notes
Stemline (STML) initiates myeloproliferative neoplasms (MPNs) clinical trial
December 16, 2014 - 11:16am | Executive Interview
Interview with George Dunbar, president and CEO of ISTO Technologies
December 16, 2014 - 9:48am | Financings
California Institute for Regenerative Medicine (CIRM) is shaking the funding “tree”
December 14, 2014 - 8:21am | Financings
StemCells (STEM) $19 M funding terminated by CIRM

Pages

footer

© 2015 RegMed Investors (regmedinvestors.com), all rights are reserved.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry MCusker . Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of RegMed Investors (RM-i); who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other RM-i media services or reposting please email hwm@regmedinvestors.com.